Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.
The AIM-traded firm said the research suggested potential applications of POLB 001 in rare and orphan blood cancers, aligning with its commitment to addressing severe medical conditions.
In addition to the promising outlook for POLB 001, Poolbeg said it intended to advance its development alongside its existing portfolio, including programmes targeting influenza, AI-driven drug discovery, and oral delivery of GLP-1 for metabolic disorders.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
